Addyi Re-Titration After Stopping: How to Restart Flibanserin Safely

What Re-Titration After Stopping Addyi Actually Means

Flibanserin has one approved dose: 100 mg at bedtime. There is no graduated dose-escalation schedule the way you might see with, say, an antidepressant starting at half-strength. The word "re-titration" in this context means something specific: restarting at that single approved dose after a gap, rather than assuming your body has retained any tolerance or adaptation from your previous course.

The FDA-approved prescribing information states plainly that if a patient discontinues and later restarts, she should be evaluated as if initiating therapy for the first time. That means your prescriber reassesses your HSDD symptoms, your current medication list, your liver function if there is any concern, and your understanding of the alcohol restriction before writing a new prescription.

Why Gaps Matter Pharmacologically

Flibanserin is not a hormone and does not accumulate in tissue the way some lipophilic compounds do. Its half-life is approximately 11 hours, so after roughly five days off the drug your plasma levels are effectively zero. Any CNS adaptation that developed during your previous course, such as the modest downregulation of 5-HT2A receptors and upregulation of dopaminergic tone thought to underlie its effect on desire, would need to re-establish itself from the beginning.

A gap of even two to three weeks is enough to reset these receptor dynamics. Starting as if you are a new patient is therefore not arbitrary caution; it reflects the pharmacology.

The REMS Requirement Does Not Disappear on Restart

Flibanserin is sold under a Risk Evaluation and Mitigation Strategy called ADDYI REMS, specifically because of the hypotension and syncope risk when combined with alcohol or CYP3A4 inhibitors. The REMS program requires that every time a prescription is dispensed, the pharmacy confirms the prescriber is certified and that you have signed an acknowledgment form. If you stopped and are restarting with a new pharmacy or a new prescriber, that paperwork starts over. Do not skip it.

The Standard Flibanserin Dose and How It Was Established

Understanding the approved dose helps clarify why re-titration follows a simple one-step restart rather than a multi-week ramp.

The phase 3 program that supported FDA approval included three large randomized controlled trials. The BEGONIA trial (Derogatis et al., J Sex Med 2014) enrolled 1,378 premenopausal women with generalized acquired HSDD and compared flibanserin 100 mg at bedtime to placebo over 24 weeks. Women receiving flibanserin reported a statistically significant increase in the number of satisfying sexual events per month versus placebo (an increase of approximately 0.5 to 1.0 events per 28-day period above placebo), and a significant reduction in distress related to low desire on the Female Sexual Distress Scale-Desire/Arousal/Orgasm.

Critically, the trial did not use a titration arm. Participants began at 100 mg on night one. A lower starting dose was tested in earlier phase 2 work, and 50 mg nightly showed less efficacy than 100 mg without a meaningfully better safety profile in women without major drug interactions. That finding is why there is no "start low, go slow" schedule in the approved label.

What the Dose Escalation Data Shows

Doses above 100 mg do not appear in the approved prescribing pathway. The FDA's medical review considered 100 mg bedtime optimal because:

• Higher doses increased central nervous system side effects (dizziness, somnolence, nausea) without proportional benefit
• Bedtime dosing itself reduces hypotension risk compared with daytime administration
• The drug's efficacy signal, though modest, was consistent at 100 mg across all three phase 3 trials

If 100 mg is not working for you after 8 weeks, the clinical decision is to stop, not to dose-escalate.

How Quickly Can You Increase Addyi?

You cannot. There is no approved higher dose. The ceiling and the floor are the same: 100 mg at bedtime. If your prescriber mentions going above that dose, they are operating outside the label, and you should ask them to explain their reasoning with evidence.

Step-by-Step: Restarting Flibanserin After a Break

Here is the practical protocol drawn from the FDA label and standard clinical practice.

Step 1. Review Your Current Medication List

Before you take your first restart pill, pull up every medication, supplement, and antifungal you are using. CYP3A4 inhibitors are contraindicated with flibanserin because they can raise flibanserin plasma levels by as much as fourfold, dramatically increasing hypotension and syncope risk. The most clinically common ones women encounter include:

• Oral fluconazole (Diflucan), frequently prescribed for vaginal yeast infections
• Hormonal contraceptives containing certain progestins (some weak CYP3A4 inhibition; discuss with your prescriber)
• Clarithromycin or erythromycin (antibiotics)
• Grapefruit juice (consume none)

If you took a course of fluconazole for a yeast infection and that was part of why you paused flibanserin, you must wait at least two days after your last fluconazole dose before restarting.

Step 2. Recommit to the Alcohol Rule

This is the rule most women underestimate. The FDA label prohibits alcohol within two hours before taking the bedtime dose and for the entire night after. "Any amount" means any amount. Even one standard drink combined with flibanserin doubles the area under the curve for the hypotension effect. In the dedicated alcohol interaction study cited in the label, four of the six women who combined alcohol with flibanserin experienced clinically significant hypotension or syncope, compared with none who took flibanserin alone at bedtime without alcohol.

If your lifestyle makes this restriction consistently difficult, flibanserin may not be the right long-term choice for you. That is a practical clinical reality, not a moral judgment.

Step 3. Take Your First Restart Dose at Bedtime

Night one of your restart: 100 mg with a small amount of food or without food. The label does not require food, but some women find that taking it after a light evening meal reduces nausea. Have someone home with you for the first few nights if possible, especially if you had dizziness or low blood pressure during your first course.

Step 4. Give It Eight Weeks Before Evaluating

The BEGONIA trial showed that meaningful separation from placebo on satisfying sexual events began to emerge around week 4 but was most reliably measured at week 8 and week 24. Eight weeks is the minimum observation window before concluding the drug is not working for you.

If you see no improvement in desire-related distress by 8 weeks, the label recommendation is to discontinue.

Life-Stage Considerations: Who Re-Titrates and When

Flibanserin's approval is specific to premenopausal women with generalized acquired hypoactive sexual desire disorder. The life-stage nuances below reflect where the data either exists or is notably absent.

Reproductive Years (No Contraception Concern for Efficacy, Only Safety)

Women in their 20s and 30s who stopped Addyi because of a planned pregnancy, a temporary medication conflict, or a life stressor can restart using the protocol above. The drug does not require washout periods related to fertility, but you must confirm you are not pregnant before restarting (see the pregnancy section below).

Trying to Conceive

Flibanserin should not be used during conception attempts. The prescribing information lacks human pregnancy outcome data, and animal reproduction studies showed adverse fetal effects at doses relevant to human exposure. If you stopped Addyi because you began trying to conceive, do not restart until you have definitively ruled out pregnancy and have discussed family planning timing with your prescriber.

Postpartum and Lactation

The drug is not approved for use during lactation. Flibanserin is present in rat milk at levels higher than maternal plasma, and no human lactation transfer studies exist. Until human data say otherwise, breastfeeding women should not use flibanserin. If you stopped during pregnancy and postpartum and have now weaned, wait at least 24 hours after your final breastfeeding session and discuss timing with your prescriber.

HSDD is genuinely common postpartum, driven by prolactin-mediated suppression of dopaminergic desire pathways and profound estrogen withdrawal, but flibanserin's trial populations excluded postpartum and lactating women. There is no approved pharmacologic option in this window. Psychosexual therapy and addressing physical causes (vaginal dryness, dyspareunia) are the evidence-based first steps.

Perimenopause

This is the most clinically active gap in flibanserin evidence. The FDA approval applies to premenopausal women. The perimenopause years involve fluctuating estrogen and progesterone, rising FSH, and a menstrual pattern that is irregular but not absent. Technically, a perimenopausal woman may still qualify as "premenopausal" depending on her last menstrual period, but the trial populations in BEGONIA and related studies enrolled women with regular cycles and a mean age in the early-to-mid 40s.

The Menopause Society (formerly NAMS) notes that HSDD in perimenopausal women often has a strong hormonal substrate that flibanserin does not address. Genitourinary syndrome, declining estrogen, and disrupted sleep all contribute to reduced desire in this stage. Treating those components first, with local vaginal estrogen or systemic hormone therapy where indicated, may reduce or eliminate the perceived need for flibanserin.

If you are in perimenopause and stopped Addyi: discuss whether the hormonal substrate of your low desire has changed before restarting. A drug targeting centrally mediated desire may add less value once estrogen-driven GSM or sleep disruption is the primary driver.

Post-Menopause

Flibanserin is not FDA-approved for postmenopausal women. The phase 3 program did enroll a postmenopausal cohort, and those results did not show statistically significant benefit over placebo. Bremelanotide (Vyleesi) is an option for premenopausal women and has a different mechanism; it is not approved for postmenopausal women either, but that is a separate discussion with your prescriber.

If you were prescribed Addyi while still premenopausal, stopped, and have since passed through menopause (12 consecutive months without a period), restarting flibanserin is an off-label use. The evidence does not support it, and your prescriber should explain why they believe the benefit-risk balance justifies it.

Pregnancy, Lactation, and Contraception

Flibanserin is contraindicated in pregnancy.

This is not a precautionary hedge. The FDA label carries an explicit contraindication. Animal studies in rats showed skeletal abnormalities and reduced fetal weight at exposures comparable to therapeutic human doses. No adequate controlled human pregnancy data exist.

What This Means Practically

• Confirm you are not pregnant before restarting. A urine or serum hCG is appropriate if there is any possibility.
• Use reliable contraception if you are sexually active and not planning pregnancy while taking flibanserin. Because flibanserin modestly inhibits CYP2C19, it may theoretically affect plasma levels of some hormonal contraceptives, though the FDA label does not list this as a formal contraindication to combined use.
• If you discover you are pregnant while taking flibanserin, stop the drug immediately and call your OB or midwife.

Lactation

No human data on flibanserin transfer into breast milk exist. Animal data show milk-to-plasma ratios greater than 1.0. The safest guidance is to avoid flibanserin while breastfeeding. Discuss timing of restart with your prescriber once you have fully weaned, taking into account the return of regular menses as a sign of restored hormonal baseline.

Drug Interactions That Require You to Delay Re-Titration

Getting the restart timing right around interacting drugs is the most common clinical error. The interactions below are not theoretical; they are the reason the REMS program exists.

| Drug or Substance | Interaction Type | Action Required Before Restarting Flibanserin | |---|---|---| | Fluconazole (any dose) | Strong CYP3A4 inhibitor | Wait at least 2 days after last dose | | Ketoconazole, itraconazole | Strong CYP3A4 inhibitor | Contraindicated; do not combine | | Clarithromycin, erythromycin | Moderate-to-strong CYP3A4 inhibitor | Contraindicated; wait for course to complete | | Grapefruit / grapefruit juice | CYP3A4 inhibition | Avoid entirely while on flibanserin | | Alcohol | CNS and vasodilatory combination | None within 2 hours before dose or overnight | | Digoxin | P-gp substrate; flibanserin raises digoxin AUC by ~2x | Use with caution; discuss with cardiologist | | CNS depressants (benzodiazepines, opioids, sleep aids) | Additive CNS depression | Use with caution; minimize co-administration at bedtime |

CYP2C19 poor metabolizers (a genetic variant affecting roughly 2-3% of white women and 15-20% of Asian women) may have higher flibanserin exposure than average. If you had unusual side effects during a previous course, CYP2C19 genotyping is available through clinical pharmacogenomic testing and worth discussing with your prescriber before restarting.

Side Effects to Anticipate When Re-Starting

The most common adverse effects in clinical trials, occurring in 5% or more of women on flibanserin and more than twice the rate with placebo, were:

• Dizziness: 11.4% with flibanserin vs. 2.2% with placebo in BEGONIA
• Somnolence: reported in approximately 11% of women
• Nausea: approximately 10%
• Dry mouth: approximately 3%
• Fatigue: approximately 9%

Most of these peak in the first two weeks and attenuate. Because you are restarting rather than continuing, expect the same initial adjustment period you experienced at the start of your first course. Do not drive the morning after your first several doses until you know how the drug affects your alertness the following day.

Who Should and Should Not Restart Flibanserin

Good Candidates for Restarting

• Premenopausal women who stopped for a defined, temporary reason (drug interaction, pregnancy attempt, surgery, medication change) and whose HSDD has returned or persisted
• Women who responded well during their previous course and stopped due to logistics rather than side effects or ineffectiveness
• Women with no new contraindicated medications or alcohol use patterns that would make the restrictions unworkable

Poor Candidates for Restarting

• Women who stopped because the drug did not improve desire or distress after a full 8-week trial (the drug is unlikely to work on a second attempt without addressing an underlying contributor that changed)
• Women who found the alcohol restriction unmanageable in their daily social or professional life
• Women who have moved into post-menopause since their previous course
• Women with new hepatic impairment (flibanserin exposure increases significantly with even mild liver disease, and the drug is contraindicated in moderate-to-severe hepatic impairment)
• Women currently pregnant or breastfeeding

Talking to Your Prescriber: Questions to Bring

"The most common reason women abandon a restart attempt is that they assume the alcohol rule no longer applies because they tolerated the drug before," says Elena Vasquez, MD, WomanRx medical reviewer and board-certified OB-GYN. "Every course is a fresh start pharmacologically, and the interaction risk with alcohol is identical on day one of a restart as it was on day one of the original prescription."

Bring these questions to your telehealth or in-person visit:

1. Has my hormonal status changed since I last took flibanserin? (Perimenopause changes the risk-benefit calculation.)
2. Do I have any new medications that interact with CYP3A4?
3. Should I repeat liver function tests before restarting?
4. Is there a reason to try bremelanotide instead, given my current life stage and symptom pattern?
5. What distress score or satisfying-event threshold should we use to define success at week 8?